5 / 34
CIN
MSI
KRAS
/
NRAS
mutations
Left
(Tumor Location)
Right
BRAF
mutations
Dienstmann et al, Nat Rev Cancer 2017
Mutation count
Copy number
CMS2
Immune activation
JAK-STAT activation
Caspases
DNA damage repair
Glutaminolysis
Lipodogenesis
Cell cycle
WNT/MYC targets
HER (ligands) expression
VEGF/VEGFR activation
Integrins activation
TGFβ activation
Mesenchymal transition
Complement activation
Immunosuppression
CMS3
CMS4
CMS1
Methylation
Poorly
immuno-
genic
Cancer-associated fibroblasts
Highly
immuno-
genic
Inflamed
immuno-
suppressive
Integrative CRC classification